Pharmaceutical use of FAM19A5 involved in regulating gliogenesis
The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
1. A method for delaying an onset of reactive gliosis in a subject in need thereof comprising administering to the subject an effective amount of an antibody or a fragment thereof that specifically binds to a family with sequence similarity 19 (FAM19A5) protein and is capable of delaying the onset of reactive gliosis within the subject.
2. The method of claim 1 , wherein the subject suffers from a central nervous system damage or a degenerative brain disease associated with reactive gliosis.
3. The method of claim 2 , wherein the central nervous system damage or the degenerative brain disease is further associated with a neuronal injury-induced increase of the number of oligodendrocyte progenitor cells expressing NG2 in the early stage of neuronal injury and/or a decrease in the TuJ positive neuron development.
4. The method of claim 2 , wherein the central nervous system damage comprises a traumatic brain injury or a spinal cord damage.
5. The method of claim 2 , wherein the degenerative brain disease comprises amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, or Parkinson's disease.
6. The method of claim 1 , wherein the antibody or the fragment thereof promotes a myelination of an axon.
7. The method of claim 1 , wherein the antibody or the fragment thereof promotes a survival of neurons.
8. The method of claim 1 , wherein the antibody is a monoclonal antibody.
9. The method of claim 1 , wherein the fragment thereof comprises a Fab, a Fab′, a F(ab′)2, a Fv fragment, a diabody, a linear antibody, a single chain antibody, or a multi-specific antibody formed from the antibody fragment.
10. The method of claim 1 , wherein the antibody is a humanized antibody.
11. The method of claim 1 , wherein the antibody is a human antibody.
12. The method of claim 1 , wherein the antibody is a chimera antibody.
13. A method for attenuating a neuronal injury-induced increase of the number of oligodendrocyte progenitor cells expressing neuron-glial antigen 2 (NG2) in an early stage of neuronal injury in a subject in need thereof comprising administering to the subject an effective amount of an antibody or a fragment thereof that specifically binds to a FAM19A5 protein and is capable of attenuating a neuronal injury-induced increase of the number of oligodendrocyte progenitor cells expressing NG2 in the early stage of neuronal injury within the subject.
14. The method of claim 13 , wherein the subject suffers from a central nervous system damage or a degenerative brain disease associated with a neuronal injury-induced increase of the number of oligodendrocyte progenitor cells expressing NG2 in the early stage of neuronal injury.
15. The method of claim 13 , wherein the antibody is a humanized antibody.
16. The method of claim 13 , wherein the antibody is a monoclonal antibody.
17. The method of claim 13 , wherein the antibody is a human antibody.
18. The method of claim 13 , wherein the fragment thereof comprises a Fab, a Fab′, a F(ab′)2, a Fv fragment, a diabody, a linear antibody, a single chain antibody, or a multi-specific antibody formed from the antibody fragment.
19. A method for increasing a TuJ positive neuron development in a subject in need thereof comprising administering to the subject an effective amount of an antibody or a fragment thereof that specifically binds to a FAM19A5 protein and is capable of increasing the TuJ positive neuron development within the subject.
20. The method of claim 19 , wherein the subject suffers from a central nervous system damage or a degenerative brain disease associated with a decrease in the TuJ positive neuron development.
21. The method of claim 19 , wherein the antibody is a humanized antibody.
22. The method of claim 19 , wherein the antibody is a monoclonal antibody.
23. The method of claim 19 , wherein the antibody is a human antibody.
24. The method of claim 19 , wherein the fragment thereof comprises a Fab, a Fab′, a F(ab′)2, a Fv fragment, a diabody, a linear antibody, a single chain antibody, or a multi-specific antibody formed from the antibody fragment.